This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.
ANTHIM
2018
2017
-
January 2017
2016
-
Animal to Human Dose Translation under the Animal Rule- Obiltoxaximab (ETI-204) Case Study
February 2016
Poster at 2016 ASM Biodefense and Emerging Diseases Research Meeting Presentations, February 8-10, 2016
-
Safety. Pharmacokinetics, and Immunogenicity of Intramuscular (IM) Administration of Oblitoxaximab (ETI-204) to Healthy Humans
February 2016
Poster at 2016 ASM Biodefense and Emerging Diseases Research Meeting Presentations, February 8-10, 2016
-
The use of meta-analysis approach to demonstrate added benefit of Obiltoxaximab (ETI-204) in treatment of inhalational anthrax
February 2016
Poster at 2016 ASM Biodefense and Emerging Diseases Research Meeting Presentations, February 8-10, 2016
-
September 2016
-
October 2016
-
October 2016
2015
-
Obiltoxaximab (ETI-204) Efficacy across a Spectrum of Disease Severity in a Trigger-to-Treat Cynomolgus Monkey Inhalational Aerosol Challenge Model of Anthrax
February 2015
Poster at 2015 ASM Biodefense and Emerging Disease Research Meeting, February 9-11, 2015
TNFRSF25
gp96
2021
-
June 4, 2021
-
2021 American Society of Clinical Oncology (ASCO) Annual Meeting - Video Presentation
Media LinkJune 4, 2021
2020
-
May 14, 2020
-
Media LinkMay 29, 2020
-
August 4, 2020
2019
-
March 2019
-
2019
-
May 29, 2019
-
June 2, 2019
-
November 5, 2019
-
November 8, 2019
-
November 8, 2019
-
November 19, 2019
2017
2016
-
2016
-
2016
-
2016
-
2016
-
2016
-
December 2016
2015
-
2015
-
2015